

## EDITORIAL

**373** Validation of PDE5 as a Chemoprevention Target

Gary A. Piazza

*See related article, p. 377*

## RESEARCH ARTICLES

**377** Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice

Bianca N. Islam, Sarah K. Sharman, Yali Hou, Allison E. Bridges, Nagendra Singh, Sangmi Kim, Ravindra Kolhe, Jimena Trillo-Tinoco, Paulo C. Rodriguez, Franklin G. Berger, Subbaramiah Sridhar, and Darren D. Browning

*See related editorial, p. 373***389** Tamoxifen Acceptance and Adherence among Patients with Ductal Carcinoma In Situ (DCIS) Treated in a Multidisciplinary Setting

Lindsey C. Karavites, Anna K. Kane, Shruti Zaveri, Yanfei Xu, Irene Helenowski, Nora Hansen, Kevin P. Bethke, Laura J. Rasmussen-Torvik, and Seema A. Khan

**398** *Fusobacterium Nucleatum* Subspecies *Animalis* Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors

Xiangcang Ye, Rui Wang, Rajat Bhattacharya, Delphine R. Boulbes, Fan Fan, Ling Xia, Harish Adoni, Nadim J. Ajami, Matthew C. Wong, Daniel P. Smith, Joseph F. Petrosino, Susan Venable, Wei Qiao, Veera Baladandayuthapani, Dipen Maru, and Lee M. Ellis

**410** Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts

Cindy Ke Zhou, Sarah E. Daugherty, Linda M. Liao, Neal D. Freedman, Christian C. Abnet, Ruth Pfeiffer, and Michael B. Cook

**421** Development of a Cancer Risk Prediction Tool for Use in the UK Primary Care and Community Settings


Aritaya Lophatananon, Juliet Usher-Smith, Jackie Campbell, Joanne Warcaba, Barbora Silarova, Erika A. Waters, Graham A. Colditz, and Kenneth R. Muir

AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

Lesions of the colon and rectum are of the most commonly diagnosed cancers, and chemoprevention is relevant due to large populations with established risk factors, and a poor prognosis for advanced disease. Phosphodiesterase-5 inhibitors are an established pharmacological approach to increase cGMP levels, which a growing body of evidence predicts will be tumor suppressive in the intestine. A study by Islam and colleagues (page 377) has tested the effect of the phosphodiesterase-5 inhibitor sildenafil in an inflammatory carcinogenesis model of colon cancer in mice. The study showed that sildenafil blocked the early carcinogenesis phase to reduce polyp formation and promoted mucus differentiation but otherwise had a minimal effect on suppressing the progression of initiated lesions. The cover image shows large pockets of differentiated tissue in a colonic polyp from a sildenafil-treated mouse that was stained to visualize mucus. Central to primary chemoprevention is a low risk-benefit ratio for drugs given to patients predisposed to disease but are otherwise healthy. This study has clear translational impact because of its use of a human dose-equivalent of sildenafil that is routinely prescribed for long-term daily use in pediatric patients with pulmonary arterial hypertension.



# Cancer Prevention Research

**10 (7)**

*Cancer Prev Res* 2017;10:373-430.

**Updated version** Access the most recent version of this article at:  
<http://cancerpreventionresearch.aacrjournals.org/content/10/7>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, contact the AACR Publications Department at [permissions@aacr.org](mailto:permissions@aacr.org).